• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr Stephen Rozzo on Regulatory Nature of Tildrakizumab for Psoriasis

Video

Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America, explains tildrakizumab’s mechanisms of action in the treatment of psoriasis and how the drug differs from other approved biologics.

The regulatory nature of tildrakizumab and its administration in office distinguish the drug from other approved biologics for psoriasis, said Stephen Rozzo, PhD, associate vice president and head, Biologics Medical Affairs, Sun Pharma, North America.


Transcript

What are the mechanisms of action for tildrakizumab in the treatment of psoriasis and how does the drug compare with other approved biologics?

The mechanism of action of tildrakizumab is not completely known, but it binds interleukin (IL)-23 p19 polypeptide, which is a pro-inflammatory molecule [that] regulates immune responses to inflammation.

It is distinct in the sense that among similar agents, it is administered by dermatologists in their offices. And for that reason, we can be sure that the patients actually get their medication as opposed to other agents administered at home.

There are other mechanisms of action for drugs that bind tumor necrosis factor and inhibit that pro-inflammatory molecule, and others that bind IL-17, a different cytokine that is pro-inflammatory. The distinction with IL-23 is its regulatory nature. In other words, it does not in itself induce inflammation as the other 2 molecules do; it regulates the response to stimuli.

Related Videos
Landman family
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions
Chase D. Hendrickson, MD, MPH
Amitkumar Mehta, MD, MBA
dr parth rali
Dr Jeffrey Sippel
christian john lillis
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.